ANI to Further Expand Rare Disease Business through Acquisition of Alimera

 Conference call scheduled for today at 8:30 a.m. ET

• Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenue
• Adds two commercial assets ILUVIEN^® and YUTIQ^® with significant growth potential, expanding ANI’s foothold in key strategic therapeutic area of ophthalmology
• Anticipated to drive high single digit to low double digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafter
• Expected to generate additional $35 - $38 million in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10 million in identified cost synergies; additional EBITDA contribution expected from accelerated growth of Purified Cortrophin^® Gel in ophthalmology
• Increased geographic diversification with Alimera’s established ex-US footprint, including direct operations in Europe

The Company’s management will host a conference call today to discuss this transaction.

Date Time Toll free (U.S.)	Monday, June 24, 2024 8:30 ET 800-225-9448

This conference call will also be webcast and can be accessed from the “Investors” section of ANI’s website at www.anipharmaceuticals.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A replay of the conference call will also be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 877-856-8965 and entering access code 4630647.

https://www.biospace.com/article/releases/ani-pharmaceuticals-to-further-expand-rare-disease-business-through-acquisition-of-alimera-sciences/